Funding Information National Natural Science Foundation from China (81301868). Science and Technology Development Program from Shandong Province (2012YD18086 and 2012YD18053).
Human epidermal growth factor receptor-2 expression in locally advanced rectal cancer: Association with response to neoadjuvant therapy and prognosis
Article first published online: 16 MAY 2014
© 2014 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd on behalf of Japanese Cancer Association.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
Volume 105, Issue 7, pages 818–824, July 2014
How to Cite
Cancer Sci (2014) 818–824
- Issue published online: 14 JUL 2014
- Article first published online: 16 MAY 2014
- Accepted manuscript online: 15 APR 2014 04:54AM EST
- Manuscript Received: 14 DEC 2014
- Manuscript Accepted: 10 APR 2014
- Manuscript Revised: 3 APR 2014
- National Natural Science Foundation from China. Grant Number: 81301868
- Science and Technology Development Program from Shandong Province. Grant Numbers: 2012YD18086, 2012YD18053
- neoadjuvant chemoradiotherapy;
- rectal cancer;
- tumor response
The aim of this study was to determine whether pretreatment status of human epidermal growth factor receptor-2 (HER-2) could predict pathologic response to neoadjuvant chemoradiotherapy (nCRT) and outcomes for patients with locally advanced rectal cancer (LARC). A total of 119 patients diagnosed with LARC received standardized multimodal treatment. Their HER-2 status was determined in pretreatment biopsies by immunohistochemistry (IHC) and FISH. Tumor response was assessed in resected regimens using the tumor regression grade system and TNM staging system. Twenty-two cases in 119 patients assessed as IHC3+ or IHC2+ plus gene-amplified were determined as HER-2 positive. Positive HER-2 status was not associated with any pretreatment clinicopathologic parameters (P > 0.05). HER-2 status could not predict pathologic response to nCRT based on downstaging (P = 0.210) and tumor regression grade (P = 0.085) but it provides us with a trend that HER-2-positive tumors may be resistant to nCRT. Positive HER-2 status was significantly associated with poor 5-year disease-free survival (P = 0.015) and 5-year overall survival (P = 0.026). It can act as a worse prognostic factor for LARC patients.